AMPA/Kainate Antagonists

Product #



Biochem/physiol Actions

Add to Cart

N193 1-Naphthylacetyl spermine trihydrochloride Blocks Ca2+ permeable AMPA receptor channels.
C239 CNQX disodium salt hydrate ≥98% (HPLC), solid CNQX(6-cyano-7-nitroquinoxaline-2,3-dioneis) is a potent, competitive AMPA/kainate receptor antagonist. It is a quinoxaline derivative and also an antagonist for non-N-methyl-d-aspartate (non-NMDA) glutamate receptor. CNQX mediates depolarization thalamic reticular nucleus via α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors (AMPARs). It displays micromolar affinity towards AMPA/kainate receptor.
Potent, competitive AMPA/kainate receptor antagonist.
C127 CNQX ≥98% (HPLC), solid Potent, competitive AMPA/kainate glutamate receptor antagonist.
C1119 Caroverine hydrochloride ≥98% (HPLC), solid Caroverine hydrochloride is a nonselective NMDA and AMPA glutamate receptor antagonist. Also, Caroverine hydrochloride is a class B calcium-channel-blocker, antiglutamatergic agent, and acts as an antioxidant when administered to lab animals.
D0540 DNQX ≥98% (TLC) A competitive kainate, quisqualate (non-NMDA) glutamate receptor antagonist.
DNQX is a quinoxaline derivative.
D1064 Dihydrokainic acid ≥98% (HPLC), powder Dihydrokainic acid is a selective inhibitor of the GLT-1 glutamate transporter. At higher concentrations, dihydrokainate is a weak inhibitor of AMPA/kainate glutamic acid receptors.
G119 GYKI 52466 hydrochloride solid Selective allosteric AMPA receptor antagonist; anti­convulsant; skeletal muscle relaxant.
SML0522 JM6 ≥97% (HPLC) JM6 is a prodrug inhibitor of kynurenine 3-monooxygenase (KMO) that increases kynurenic acid levels and reduces extracellular glutamate in the brain. JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss in mouse model of Alzheimer disease.
SML1747   JNJ-55511118 ≥98% (HPLC) JNJ-55511118 is also known as 5-[2-chloro-6-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one. It acts as an anticonvulsant or neuroprotectant. It is considered as a reversible α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibitor, mainly in the hippocampus region.
JNJ-55511118 is an orally available, brain penetrant, potent and selective negative modulator of AMPA receptors that requires the presence of the accessory protein CACNG8 (TARP-γ8). JNJ-55511118 exhibit potent inhibition of neurotransmission within hippocampus, and a strong anti-convulsant effect.
K3375 Kynurenic acid ≥98% Kynurenic acid (KynA) is a non-selective antagonist of N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors. It blocks kainic acid neurotoxicity. Kynurenic acid also blocks nicotinic acetylcholine receptors. It is a by-product of tryptophan catabolic pathway. Kynurenic acid is a neuromodulator and controls the levels of glutamate, dopamine, acetylcholine and α-aminobutyric acid (GABA). KynA controls neuroendocrine functions and altered levels of KynA is a potential marker in depression, schizophrenia Alzheimer′s and Huntington′s diseases. Normal levels of KynA in the brain is crucial for the cognitive function.
N183 NBQX disodium salt hydrate ≥98% (HPLC) NBQX disodium salt hydrate is a neuroprotective AMPA/kainate glutamate receptor antagonist.
N171 NBQX hydrate powder, ≥98% (HPLC) Neuroprotective AMPA/kainate glutamate receptor antagonist.
N179 NS 102 solid Competitive glutamate receptor antagonist with high selectivity for the low-affinity [3H] kainate binding site.
PZ0144 PD-161989 2-Hydroxyethanesulfonate ≥98% (HPLC) PD-161989 is an AMPA receptor antagonist.
SML0686 Talampanel ≥97% (HPLC) Talampanel ia a specific noncompetitive AMPA receptor antagonist and anticonvulsant.
SML0718   UBP714 ≥95% (HPLC) UBP714 is a derivative of the NMDA receptor negative allosteric modulator UBP608 (SML0606). UBP714 potentiates the activity of recombinant GluN1/GluN2 NMDA receptors, and enhances NMDA receptor mediated EPSPs in the CA1 region of the hippocampus.
Z4777 ZK 200775 hydrate ≥98% (HPLC), powder  
G111 γ-D-Glutamylaminomethylsulfonic acid solid Gamma-D-Glutamylaminomethylsulfonic acid (GAMS) is used as a selective antagonist of AMPA/kainate glutamatergic receptors and as an anticonvulsant.